A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer (Q36188532)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Rocío García-Carbonero

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Eduardo García-Rico

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Cristina Gravalos

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Antonieta Salut

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Carlos García-Girón

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Ana Isabel León

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Isabel Sevilla

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Joan Maurel

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Beatriz Esteban

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Adolfo Murias

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Hernán Cortés-Funes

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

19 July 2012

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Clinical and Translational Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

606-612

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

copyright license

Creative Commons Attribution 2.0 Generic

19 July 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

NCCN Clinical Practice Guidelines in Oncology: colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

1 October 2017

Optimal treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

1 October 2017

Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

1 October 2017

Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

1 October 2017

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

1 October 2017

Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

1 October 2017

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

1 October 2017

Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

1 October 2017

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

2 July 2018

A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

2 July 2018

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Angina related to 5-Fluorouracil

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

Raltitrexed plus oxaliplatin in the treatment of metastatic colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

22 September 2018

Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3427491

22 September 2018

Cancer incidence and mortality in Europe, 2004

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0843-X

21 January 2018

A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NCCN Clinical Practice Guidelines in Oncology: rectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855138

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12094-012-0843-X

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855138%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36188532&oldid=2198314752"